Compare Illumina, Inc. (ILMN) vs Tapestry, Inc. (TPR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Tapestry, Inc. — how do they compare? Illumina, Inc. trades at $193.06 (market cap $28.96B), while Tapestry, Inc. trades at $161.95 (market cap $33.29B). The key difference: Illumina, Inc. and Tapestry, Inc. are close in size by market cap, and Tapestry, Inc. pays a 0.97% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals.
| ILMN | TPR | |
|---|---|---|
Market Cap | $28.96B | $33.29B |
Sector | Health | Consumer Cyclical |
52-Week High | $205.10 | $164.78 |
52-Week Low | $91.00 | $95.69 |
Enterprise Value | $30.32B | $36.15B |
Dividend Yield | — | 0.97% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $187.96, down 2.97% on the day, but maintains strong fundamental momentum with three consecutive quarterly earnings beats. The stock shows robust profitability with 66.38% gross margins and 18.34% net income margins, though technical indicators suggest near-term bearish pressure. Recent institutional buying activity and positive analyst coverage (51% buy ratings) support the stock's long-term growth narrative in the genomics sector.
The outlook remains positive with a consensus price target of $201.58 representing 7% upside potential. Key catalysts include continued NovaSeq X adoption and AI partnerships, while risks involve competitive pressures and execution challenges in achieving projected revenue growth. The company's turnaround from net losses to $850M profit in 2025 demonstrates improved operational efficiency.
TPR trades at $162.36, up 0.22% today, and is near its 52-week high with strong bullish technical signals. The company has consistently beaten earnings expectations, with Q1 2026 EPS of $1.66 exceeding the $1.30 estimate. Recent news highlights AI integration and brand momentum, while analyst consensus is strongly bullish with a $190.33 price target.
Outlook remains positive driven by earnings growth and strategic initiatives, but risks include high valuation multiples and volatile cash flows. The stock offers upside to analyst targets but faces margin pressure and competitive challenges in the retail sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Tapestry, Inc.
Coach, Kate Spade, and Stuart Weitzman are the fashion and accessory brands that comprise Tapestry. The firm's products are sold through about 1,400 company-operated stores, wholesale channels, and e-commerce in North America (67% of fiscal 2022 sales), Europe, Asia (28% of fiscal 2022 sales), and elsewhere. Coach (74% of fiscal 2022 sales) is best known for affordable luxury leather products. Kate Spade (22% of fiscal 2022 sales) is known for colorful patterns and graphics. Women's handbags and accessories produced 69% of Tapestry's sales in fiscal 2022. Stuart Weitzman, Tapestry's smallest brand, generates nearly all its revenue from women's footwear.
Read more on TPR →
